Aspartate Aminotransferase (AST) to Lymphocyte Ratio Index (ALRI) for Predicting Survival in Patients with Hepatocellular Carcinoma

Parameters:

(1) serum AST in U/L

(2) absolute lymphocyte count in 10^9/L

AST to lymphocyte ratio =

= (AST) / (absolute lymphocyte count)

Interpretation:

• An ALRI > 25.2 had a worse overall survival (5 Year overall survival 20% vs 40%).

Performance:

• The area under the ROC curve is 0.66.

Prognostic factors for overall survival:

(1) ALRI > 25.2

(2) TNM stage III or IV

(3) tumor diameter > 5 cm

(4) recurrence